Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data

Respiratory Medicine

Volumn 104, Issue 9, 2010, Pages 1381-1385

  Molimard, M ^a   Buhl, R ^b   Niven, R ^c   Le Gros, V ^d   Thielen, A ^e   Thirlwell, J ^f   Maykut, R ^g   Peachey, G ^f  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d NOVARTIS PHARMA K K   (Japan)

^e NOVARTIS PHARMA GMBH   (Germany)

^f NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic asthma; Anti IgE; Oral corticosteroids

Indexed keywords

OMALIZUMAB; PREDNISOLONE;

ADULT; ALLERGIC ASTHMA; ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DATABASES, FACTUAL; FEMALE; FRANCE; GERMANY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RESPIRATORY HYPERSENSITIVITY;

EID: 77955663329     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.06.001     Document Type: Article

References (15)

1. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, and J. Bousquet et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
2. J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, and S. Wenzel et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
3. S.P. Peters, G. Ferguson, Y. Deniz, and C. Reisner Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment Respir Med 100 2006 1139 1151
4. J.R. Curtis, A.O. Westfall, J. Allison, J.W. Bijlsma, A. Freeman, and V. George et al. Population-based assessment of adverse events associated with long-term glucocorticoid use Arthritis Rheum 55 2006 420 426
5. F. Ducharme, Z. Schwartz, G. Hicks, and R. Kakuma Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma Cochrane Database Syst Rev 2 2004 CD003133
6. D.J. Evans, P. Cullinan, and D.M. Geddes Cyclosporin as an oral corticosteroid sparing agent in stable asthma Cochrane Database Syst Rev 2 2001 CD002993
7. H. Davies, L. Olson, and P. Gibson Methotrexate as a steroid sparing agent for asthma in adults Cochrane Database Syst Rev 2 2000 CD000391
8. European Medicines Agency (EMEA) Omalizumab (Xolair®) full prescribing information (EU) Available at: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/Xolair/emea-combined-h606en.pdf August 2009 Accessed 14 09 2009
9. G. D'Amato Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases Eur J Pharmacol 533 2006 302 307 (Pubitemid 43340021)
10. M. Molimard, F. de Blay, A. Didier, and V. Le Gros Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France Respir Med 102 2008 71 76
11. R. Niven, and D. Mcbryan A UK survey of oral corticosteroid use in patients treated with omalizumab Thorax 62 Suppl. 3 2007 A98 Abstract P91
12. S. Korn, A. Thielen, S. Seyfried, C. Taube, O. Kornmann, and R. Buhl Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany Respir Med 103 2009 1725 1731
13. H. Milgrom, R.B. Fick Jr., J.Q. Su, J.D. Reimann, R.K. Bush, and M.L. Watrous et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group N Engl J Med 341 1999 1966 1973
14. W.W. Busse, M. Massanari, F. Kianifard, and G.P. Geba Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis Curr Med Res Opin 23 2007 2379 2386
15. S.T. Holgate, A.G. Chuchalin, J. Hébert, J. Lötvall, G.B. Persson, and K.F. Chung et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638